Evidence map›Paper›PMID 40116873›Full record

ReviewNaunyn-Schmiedeberg's archives of pharmacology2025

NLRP3 inflammasome-based therapies by natural products: a new development in the context of cancer therapy.

Hamza Abu Owida, Ahmed Yaseen Abed, Farag M A Altalbawy, Malathi H, Vikrant Abbot, Sanoeva Matlyuba Jakhonkulovna, Suleiman Ibrahim Mohammad, Asokan Vasudevan, Reem Mohsin Khalaf, Ahmed Hussein Zwamel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Mechanistic insights into natural product-driven modulation of NLRP3-inflammasome signalling in metabolic syndrome.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hamza Abu OwidaDepartment of Medical Engineering, Faculty of Engineering, Al-Ahliyya Amman University, Amman, 19328, Jordan.
Ahmed Yaseen AbedDepartment of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Ramadi, Al Anbar, 31001, Iraq. ahmed.yassin@uoa.edu.iq.
Farag M A AltalbawyDepartment of Chemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia.
Malathi HDepartment of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India.
Vikrant AbbotChandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali, 140307, Punjab, India.
Sanoeva Matlyuba JakhonkulovnaDepartment of Neurology, vice rektor of Bukhara State Medical Institute, Bukhara, Uzbekistan.
Suleiman Ibrahim MohammadElectronic Marketing and Social Media, Economic and Administrative Sciences, Zarqa University, Zarqa, Jordan.
Asokan VasudevanFaculty of Business and Communications, INTI International University, 71800, Negeri Sembilan, Malaysia.
Reem Mohsin KhalafMazaya University College, Nasiriyah, Dhiqar, Iraq.
Ahmed Hussein ZwamelDepartment of Medical Analysis, Medical Laboratory Technique College, the Islamic University, Najaf, Iraq.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The leucine-rich repeat containing protein (NLR) canonical inflammasome family includes Nod-like receptor protein 3 (NLRP3). Via the mediation of apoptosis proteins and immunological reactions, it controls the pathogenesis of malignancy. Experimental studies showed a relationship among lymphogenesis, cancer metastasis, and NLRP3 expression. Natural products have also been used as lead-based substances in a number of investigations to speed up the creation of novel, specific NLRP3 inhibitors. Via the mediation of apoptotic proteins and immunological responses, it controls the pathogenesis of malignancy. Moreover, it was recently noted that among human cancers, chemotherapy activates NLRP3. Induction of NLRP3 could encourage the generation of IL-1β and IL-22 to facilitate the propagation of malignancy. Additionally, prior research has demonstrated that the usage of NLRP3 in cancer therapy may result in resistance to drugs. The depletion of NLRP3 could affect the survival of cells. Natural products have been used as lead materials in a number of studies to help generate novel, specific NLRP3 antagonists more quickly. In the present review, we examine the mechanism behind the beneficial effects of the natural substances on the inhibition of cancer growth and progression, with special focus on NLRP3 regulation.

Indexed as

Antineoplastic AgentsBiological ProductsInflammasomesNeoplasmsNLR Family, Pyrin Domain-Containing 3 ProteinAnimalsHumansAntineoplastic AgentsBiological ProductsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanCancerImmune responseNatural productsNLRP3

Identifiers

PMID40116873

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.